NO341685B1 - Kontroll av gjennombruddsblødning i utvidede hormonelle svangerskapsforebyggende regimer - Google Patents

Kontroll av gjennombruddsblødning i utvidede hormonelle svangerskapsforebyggende regimer

Info

Publication number
NO341685B1
NO341685B1 NO20065499A NO20065499A NO341685B1 NO 341685 B1 NO341685 B1 NO 341685B1 NO 20065499 A NO20065499 A NO 20065499A NO 20065499 A NO20065499 A NO 20065499A NO 341685 B1 NO341685 B1 NO 341685B1
Authority
NO
Norway
Prior art keywords
control
hormonal contraceptive
breakthrough bleeding
contraceptive regimens
extended
Prior art date
Application number
NO20065499A
Other languages
English (en)
Norwegian (no)
Other versions
NO20065499L (no
Inventor
Andreas Sachse
Patricia J Sulak
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO341685(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of NO20065499L publication Critical patent/NO20065499L/no
Publication of NO341685B1 publication Critical patent/NO341685B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
NO20065499A 2004-04-30 2006-11-28 Kontroll av gjennombruddsblødning i utvidede hormonelle svangerskapsforebyggende regimer NO341685B1 (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10
PCT/EP2005/004777 WO2005105103A2 (en) 2004-04-30 2005-04-29 Management of breakthrough bleeding in extended hormonal contraceptive regimens

Publications (2)

Publication Number Publication Date
NO20065499L NO20065499L (no) 2006-11-29
NO341685B1 true NO341685B1 (no) 2017-12-18

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065499A NO341685B1 (no) 2004-04-30 2006-11-28 Kontroll av gjennombruddsblødning i utvidede hormonelle svangerskapsforebyggende regimer

Country Status (29)

Country Link
US (3) US8163721B2 (https=)
EP (1) EP1747001B1 (https=)
JP (4) JP2007535519A (https=)
KR (4) KR101812160B1 (https=)
CN (1) CN103127156A (https=)
AR (1) AR048722A1 (https=)
AU (1) AU2005237255B2 (https=)
BR (1) BRPI0510493A (https=)
CA (1) CA2562296A1 (https=)
CR (1) CR8709A (https=)
DK (1) DK1747001T3 (https=)
EA (2) EA031227B1 (https=)
EC (1) ECSP066999A (https=)
ES (1) ES2704999T3 (https=)
HU (1) HUE041475T2 (https=)
IL (1) IL178458A (https=)
LT (1) LT1747001T (https=)
MX (1) MXPA06012567A (https=)
MY (1) MY151322A (https=)
NO (1) NO341685B1 (https=)
NZ (1) NZ586107A (https=)
PA (1) PA8631801A1 (https=)
PE (1) PE20060467A1 (https=)
SG (2) SG10201701904TA (https=)
SI (1) SI1747001T1 (https=)
SV (1) SV2006002100A (https=)
TW (1) TWI374735B (https=)
UY (1) UY28875A1 (https=)
WO (1) WO2005105103A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
JP2012502988A (ja) * 2008-09-16 2012-02-02 プレイテックス プロダクツ エルエルシー 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法
WO2010042607A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc Transdermal delivery
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
WO2010042612A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
MD3310333T2 (ro) 2015-06-18 2020-06-30 Estetra Sprl Unitate de dozare orodispersabilă care conține un component estetrol
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
CN116077454A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
CA2989975C (en) * 2015-06-23 2021-10-12 Laboratorios Leon Farma Sa Drospirenone-based contraceptive for a female patient affected with excess weight
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
DK3781171T3 (da) 2018-04-19 2022-05-02 Estetra Srl Sammensætninger og deres anvendelser til lindring af menopause-associerede symptomer
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022110A2 (en) * 2000-09-14 2002-03-21 Schering Aktiengesellschaft Contraception process and administration form for the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) * 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
KR100518102B1 (ko) * 1996-07-26 2005-10-04 와이어쓰 프로게스틴과 에스트로겐의 혼합물을 포함하는 단일상 피임약 키트
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
SI1214076T1 (en) * 1999-08-31 2004-06-30 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022110A2 (en) * 2000-09-14 2002-03-21 Schering Aktiengesellschaft Contraception process and administration form for the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KLIPPING C. ET AL. " Contracepetive Efficacy and tolerability of ethynylestradiol 20 micro g/drospirenone 3 mg in a flexible extended regimen: en open-label, multicentre, randomised, controlled study" J. Fam Plann Reprod Health Care , 2012, 38, side 73.83, doi: 10.1136/jfprhc-2011-100213, Dated: 01.01.0001 *
SILLEM M, ET AL.: "USE OF AN ORAL CONTRACEPTIVE CONTAINING DROSPIRENONE IN AN EXTENDED REGIMEN", EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, PARTHENON PUBLISHING GROUP, CARNFOORTH, GB, vol. 08, no. 03, 1 September 2003 (2003-09-01), GB , pages 162 - 169, XP008064769, ISSN: 1362-5187 *

Also Published As

Publication number Publication date
IL178458A (en) 2016-08-31
JP2017048253A (ja) 2017-03-09
SV2006002100A (es) 2006-02-15
JP2015187157A (ja) 2015-10-29
CR8709A (es) 2007-08-28
US20150174142A1 (en) 2015-06-25
SG152288A1 (en) 2009-05-29
TWI374735B (en) 2012-10-21
UY28875A1 (es) 2005-11-30
AU2005237255B2 (en) 2011-07-07
MY151322A (en) 2014-05-15
US20120202779A1 (en) 2012-08-09
EA201200377A1 (ru) 2012-08-30
HUE041475T2 (hu) 2019-05-28
JP2007535519A (ja) 2007-12-06
EA201200377A8 (ru) 2018-01-31
CA2562296A1 (en) 2005-11-10
SI1747001T1 (sl) 2019-02-28
EP1747001A2 (en) 2007-01-31
SG10201701904TA (en) 2017-05-30
AU2005237255A1 (en) 2005-11-10
ES2704999T3 (es) 2019-03-21
ECSP066999A (es) 2006-12-29
KR101812160B1 (ko) 2017-12-27
TW200603781A (en) 2006-02-01
EP1747001B1 (en) 2018-10-10
EA016625B1 (ru) 2012-06-29
US20050250747A1 (en) 2005-11-10
KR20160150113A (ko) 2016-12-28
IL178458A0 (en) 2008-04-13
PE20060467A1 (es) 2006-06-11
WO2005105103A2 (en) 2005-11-10
JP2013018787A (ja) 2013-01-31
NO20065499L (no) 2006-11-29
JP6134491B2 (ja) 2017-05-24
KR20150058555A (ko) 2015-05-28
NZ586107A (en) 2012-05-25
MXPA06012567A (es) 2006-12-15
WO2005105103A3 (en) 2006-09-08
JP6153967B2 (ja) 2017-06-28
BRPI0510493A (pt) 2007-11-13
DK1747001T3 (en) 2019-02-04
KR20130022425A (ko) 2013-03-06
EA200601908A1 (ru) 2007-04-27
KR20070004919A (ko) 2007-01-09
CN103127156A (zh) 2013-06-05
PA8631801A1 (es) 2006-11-09
EA031227B1 (ru) 2018-12-28
AR048722A1 (es) 2006-05-17
LT1747001T (lt) 2019-01-25
US8163721B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
NO341685B1 (no) Kontroll av gjennombruddsblødning i utvidede hormonelle svangerskapsforebyggende regimer
ECSP088097A (es) Nuevos regímenes para dispositivos de administración controlada de fármacos para anticoncepción
DK1620392T3 (da) Hydroxy-biphenyl-carbaldehydoxim-derivater og deres anvendelse som östrogene midler
NO20070723L (no) Progesteron reseptormodulatorer inneholdende pyrrol-oksindolderivater og deres anvendelse
NO20073482L (no) Fremgangsmåte til å stabilisere antidement medikament
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
ATE497745T1 (de) Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20052476D0 (no) 2-alkyl-(2-amino-3-aryl-propionyl)-piperazinderivater og beslektede forbindelser som melanokortinreseptorligander for behandlingen av obesitet.
NO20045217L (no) Anvendelse av tio-oxindolderivater for behandling av hormon relaterte tilstander
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
EP1827446A4 (en) SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND URETINS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS WITH ARENA VIRUSES
NO20076683L (no) Cyanopyrrol-sulfonamid progesteron reseptormodulatorer og deres anvendelse
MXPA05008347A (es) Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis.
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression
DK1732921T3 (da) Thiomidderivater som progesteronreceptormodulatorer
NO20065903L (no) Ny assosiasjon av en sinusknute If strominhibitor og en kalsiuminhibitor, og farmasoytiske sammensetninger inneholdende den
TW200744610A (en) New regimens for controlled drug delivery devices for contraception
UA91190C2 (ru) Контроль прорывных кровотечений при пролонгированном режиме приема гормональных контрацептивов
ATE448215T1 (de) Selektive östrogen-rezeptor-modulatoren
NO20030606D0 (no) Modifisert gj¶r og anvendelser derav, n¶rmere bestemt for fremstilling avsteroidderivater
项俐 My prince
何玲 Face the music
DE602005011029D1 (de) Therapeutisches mittel zur behandlung von plasmazellneoplasien
朱玲麟 On Translation of Kinship Terms

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE